“I’d love there to be a better agent,” says a thought leader on the current state of sarcoidosis treatment. Many
sarcoidosis patients require little or no treatment, but patients with chronic disease need a therapy that is safer
than the corticosteroids that have become the mainstay treatment for the disease. Because substantial market
constraints have limited development in this therapeutic area, only a few novel agents are in the pipeline.
However, opportunity remains for an agent that can address some of the unmet needs in this market.
Questions Answered in This Report
Sarcoidosis is an infl ammatory disease that is hallmarked by
the development of granulomas. What organ
systems are affected by sarcoidosis? How is the disease diagnosed? What is the prognosis for patients
with sarcoidosis?
Sarcoidosis affects only a small percentage of the population. How many people were hospitalized with
sarcoidosis in 2008? Is this population expected to grow?
Patients with chronic sarcoidosis will require multiple treatment courses throughout their lifetime. What
are the current treatments for sarcoidosis? What are their benefi ts and drawbacks? How do emerging
treatments compare with current offerings?
Reimbursement challenges loom large in this market. What effect are they having on sales? How might
companies overcome these challenges? What are the ideal characteristics of an agent positioned to
capture the sarcoidosis market?
Scope
Overview of sarcoidosis: Pathophysiology and etiology, symptoms, diagnosis.
Epidemiology: Decision Resources epidemiology analysis of the diagnosed incidence and the
number of patients hospitalized with sarcoidosis in the United States, 2008-2018.
Current treatments: Corticosteroids, methotrexate, antimalarials, TNF-á inhibitors.
(0 items)
